Pfizer (NYSE:PFE) Trading Down 1% – Time to Sell?

Posted by Geri Gentry on Aug 27th, 2026

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price fell 1% during mid-day trading on Thursday . The stock traded as low as $27.83 and last traded at $28.0050. Approximately 29,931,103 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 41,855,605 shares. The stock had previously closed at $28.30.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

Positive Sentiment: Pfizer provided an update from its Korean post-marketing study of Vyndamax for transthyretin amyloid cardiomyopathy (ATTR-CM). Additional real-world evidence could support the drug’s commercial durability and strengthen confidence in Pfizer’s rare-disease portfolio. Pfizer’s Korean Vyndamax Study Update
Positive Sentiment: Pfizer has begun the European Medicines Agency review of its Lyme disease vaccine candidate. Regulatory review is an important step toward potentially expanding the company’s future vaccine revenue base, although approval and commercialization remain uncertain. Pfizer Starts EMA Review for Its Lyme Disease Vaccine
Positive Sentiment: Commentary on Pfizer’s pipeline and oncology portfolio argues that valuation and diversification may offer turnaround potential if newer medicines offset declining legacy products. Pfizer’s latest quarterly results also exceeded consensus estimates, with revenue growth and earnings of $0.77 per share versus expectations of $0.68.
Neutral Sentiment: Pfizer remains a prominent high-yield dividend stock, but comparisons with Abbott emphasize the trade-off: Pfizer offers income and potential recovery upside, while Abbott has steadier diversification and dividend-growth characteristics. Pfizer vs. Abbott Dividend Comparison
Negative Sentiment: Investors are increasingly focused on Pfizer’s dividend sustainability rather than its headline payout ratio, which is above 100%. The key risks are free-cash-flow generation, debt and whether cost reductions can support the payout while the company rebuilds growth. The Most Concerning Thing About Pfizer’s Dividend
Negative Sentiment: Critics say Pfizer’s turnaround case relies heavily on cost savings and targets that do not imply meaningful growth until later in the decade. Patent expirations and declining volumes could therefore remain overhangs, helping explain why brokerages maintain a consensus “Hold” rating. Can Cost Cuts and 2030 Targets Save Pfizer Stock?

Analyst Ratings Changes

Several equities analysts have weighed in on PFE shares. Wolfe Research reaffirmed an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Cantor Fitzgerald restated a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Monday, July 6th. UBS Group reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Guggenheim decreased their target price on shares of Pfizer from $35.00 to $31.00 and set a “buy” rating for the company in a research note on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $28.28.

Get Our Latest Stock Analysis on Pfizer

Pfizer Stock Performance

The firm has a 50-day simple moving average of $25.44 and a two-hundred day simple moving average of $26.29. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $159.62 billion, a price-to-earnings ratio of 36.85 and a beta of 0.34.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently modified their holdings of PFE. California State Teachers Retirement System increased its position in Pfizer by 2,320.6% during the second quarter. California State Teachers Retirement System now owns 217,981,455 shares of the biopharmaceutical company’s stock worth $5,248,993,000 after buying an additional 208,976,273 shares during the last quarter. Studio Investment Management LLC lifted its position in shares of Pfizer by 16.2% in the second quarter. Studio Investment Management LLC now owns 37,694 shares of the biopharmaceutical company’s stock worth $908,000 after buying an additional 5,249 shares during the last quarter. Henrickson Nauta Wealth Advisors Inc. bought a new stake in shares of Pfizer during the 2nd quarter worth about $328,000. Kintra Wealth LLC increased its holdings in shares of Pfizer by 14.8% during the 2nd quarter. Kintra Wealth LLC now owns 56,271 shares of the biopharmaceutical company’s stock valued at $1,355,000 after acquiring an additional 7,248 shares during the last quarter. Finally, Widmann Financial Services Inc. increased its holdings in shares of Pfizer by 6.4% during the 2nd quarter. Widmann Financial Services Inc. now owns 58,355 shares of the biopharmaceutical company’s stock valued at $1,405,000 after acquiring an additional 3,485 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

(Get Free Report)

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.